SCHEMBL7814795

SCHEMBL7814795

CC(C)(C)c1cccc(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
RAB9A P51151 1/20 0.60
ASIC3 Q9UHC3 1/20 0.50
SYK P43405 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR7 P34969 1/20 0.40
KAT6A Q92794 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
ADORA2A P29274 3/20 0.39
ADORA1 P30542 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
MAPT P10636 4/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23746886 0.89 MEN1 (0.47) MEN1KMT2ARAB9AASIC3SYK
SCHEMBL11931991 0.88 MEN1 (0.60) MEN1KMT2ARAB9AASIC3ALDH1A1
SCHEMBL15290157 0.84 CCR1 (0.46) MEN1KMT2ARAB9ASYKKDM4E
SCHEMBL31084593 0.84 CCR1 (0.46) MEN1KMT2ARAB9ASYKKDM4E
SCHEMBL5646308 0.84 MEN1 (0.56) MEN1KMT2ARAB9AASIC3ALDH1A1
SCHEMBL10056535 0.83 MEN1 (0.65) MEN1KMT2ARAB9AASIC3ALDH1A1
SCHEMBL26700331 0.82 SCN9A (0.41) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL2733408 0.82 CNR2 (0.40) MEN1KMT2ARAB9AALDH1A1CNR2
SCHEMBL16077971 0.82 CCR1 (0.44) MEN1KMT2ARAB9ASYKALDH1A1
SCHEMBL15977775 0.81 SYK (0.40) MEN1KMT2ARAB9AASIC3SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12035618-B2 Electroluminescent devices UNIVERSAL DISPLAY CORPORATION (US) 2024-07-09 US disclosed
US-12035618-B2 Electroluminescent devices UNIVERSAL DISPLAY CORPORATION (US) 2024-07-09 US disclosed
US-20240224783-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-07-04 US disclosed
US-11917900-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-02-27 US disclosed
US-11917900-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-02-27 US disclosed
US-11864458-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-01-02 US disclosed
US-11864458-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-01-02 US disclosed
US-20230389407-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-11-30 US disclosed
US-20230389421-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-11-30 US disclosed
US-20230389421-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-11-30 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-7557213-B2 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2009-07-07 US disclosed
US-20080107624-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20080107623-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20080107625-A1 Inhibitors of Hepatitis C Virus BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20070167443-A1 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2007-07-19 US disclosed
US-20070099825-A1 ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients BRISTOL-MYERS SQUIBB COMPANY 2007-05-03 US disclosed
US-20070029528-A1 Compositions and methods for facilitating reaction at room temperature SAN DIEGO STATE UNIVERSITY FOUNDATION (US) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 MEN1 3838/4885KMT2A 2891/4885RAB9A 333/4885
US-20080107623-A1 Inhibitors of Hepatitis C Virus HAVCR2, HCCS, VIP MEN1 3909/4885KMT2A 4411/4885RAB9A 963/4885
US-20070099825-A1 ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients TERT, VIP, YWHAZ MEN1 4760/4885KMT2A 3526/4885RAB9A 1186/4885
US-20080107624-A1 Inhibitors of Hepatitis C Virus HAVCR2, MRPS23, HCCS MEN1 3911/4885KMT2A 4324/4885RAB9A 881/4885
US-12035618-B2 Electroluminescent devices ELAVL1, ELAVL3, JUND MEN1 3990/4885KMT2A 3523/4885RAB9A 1457/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 MEN1 3838/4885KMT2A 2891/4885RAB9A 333/4885
US-11864458-B2 Organic electroluminescent materials and devices RAP1A, L1CAM, SOD1 MEN1 2774/4885KMT2A 1364/4885RAB9A 676/4885
US-20070167443-A1 Substituted quinolones and methods of use TOP2A, NQO2, TOP2B MEN1 1755/4885KMT2A 1633/4885RAB9A 1645/4885
US-20240224783-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, ICOSLG MEN1 3094/4885KMT2A 3450/4885RAB9A 1884/4885
US-20080107625-A1 Inhibitors of Hepatitis C Virus HAVCR2, HCCS, VIP MEN1 3909/4885KMT2A 4411/4885RAB9A 963/4885
US-20230389407-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SNRPD2, HNRNPDL, SNRPA MEN1 3015/4885KMT2A 4056/4885RAB9A 874/4885
US-11917900-B2 Organic electroluminescent materials and devices OTC, OSBP, OCIAD2 MEN1 3227/4885KMT2A 4115/4885RAB9A 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.